Alembic Pharmaceuticals

US Product Launches And India Execution Will Expand Reach

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

09 Feb 25

Updated

05 Sep 25

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

-13.5%

7D

-0.3%

Loading

1Y

-13.5%

7D

-0.3%

You can edit this narrative until Sep 6 10:20 AM. Then, changes will post as Updates.

Author's Valuation

₹1.06k14.7% undervalued

AnalystConsensusTarget Fair Value

Shared on 05 Sep 25

As both net profit margin and revenue growth forecasts for Alembic Pharmaceuticals remain stable, the consensus analyst price target is unchanged at ₹1057. What's in the News Alembic Pharmaceuticals received USFDA final approval for Macitentan Tablets, 10 mg, a generic of Opsumit, targeting a USD 1,180 million market.

Shared on 06 May 25

Fair value Decreased 3.47%

Shared on 01 May 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

Fair value Increased 0.35%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Increased 4.41%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

Fair value Decreased 1.10%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 12 Mar 25

Fair value Increased 2.97%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget Fair Value

₹1.06k

14.7% undervalued

Future estimation in

% p.a.

0

Decrease

Increase

Current revenue growth rate

9.90%

Pharma revenue growth rate

0.66%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

12.76%

Calculation

₹11.48b

Earnings '28

x

25.71x

PE Ratio '28

=

₹295.16b

Market Cap '28

₹295.16b

Market Cap '28

/

195.86m

No. shares '28

=

₹1.51k

Share Price '28

₹1.51k Share Price '28

Discounted to 2025 @ 12.73% p.a.

=

₹1.05k

Fair Value '25